Skip to main content
Top
Published in: Pituitary 5/2017

01-10-2017

Acromegaly: surgical results in 548 patients

Authors: Cecilia Fernández Mateos, Maria García-Uria, Tomás Lucas Morante, José García-Uría

Published in: Pituitary | Issue 5/2017

Login to get access

Abstract

Purpose

The goal of this study was to quantified the results of microsurgery, in all the patients with acromegaly treated by the same endocrinologist and the same surgeon between 1975 and 2015.

Methods

A series of 548 patients with acromegaly were operated and followed-up from 6 months to 40 years. Patients were selected according to five criteria: (1) Operated by the same surgeon. (2) No previous treatment. (3) Complete endocrinological preoperative studies including GH, OGTT, IGF-I, PRL test and TC/MRI. (4) Complete postoperative endocrinological evaluation for at least one determination of GH, OGTT, PRL test and IGF-I six months after surgery. (5) All the patients were supervised by the same endocrinologist.

Results

Microadenomas were present in 119 patients and 109 (91,5%) achieved remission. Non invasive macroadenomas were present in 200 patients and 164 achieved remission (82%). Results were worse for invasive macroadenomas but even with great invasions some patients achieved clinical remission. Follow-up range from 6 months to 40 years (mean 3.3 ± 2.3) A long term follow-up of 15 years was achieved in 61 patients. Four of them had a recurrence 4, 7, 8, 12 years after surgery (6.5%). There was not mortality and the rate of complications was low.

Conclusions

Surgery remains the first line of therapy for a majority of acromegalic patients. This series proves to be very valuable in circumscribed adenomas but also in invasive tumours. Levels of GH and IGF-I were decreased in almost all the patients without remission.
Literature
2.
go back to reference Wilson CB (1990) Role of surgery in the management of pituitary tumors. Neurosurg Clin N Am 1(1):139–159PubMed Wilson CB (1990) Role of surgery in the management of pituitary tumors. Neurosurg Clin N Am 1(1):139–159PubMed
3.
go back to reference Fahlbusch R, Buchfelder J (2001) Surgical management of acromegaly. In: Wass J (ed) Handbook of acromegaly. BioScientifica, Bristol, pp 41–47 Fahlbusch R, Buchfelder J (2001) Surgical management of acromegaly. In: Wass J (ed) Handbook of acromegaly. BioScientifica, Bristol, pp 41–47
4.
go back to reference García-Uria J, Del Pozo J, Bravo G et al (1978) Functional treatment of acromegaly by transphenoidal microsurgery. J Neurosurg 49:36–40CrossRefPubMed García-Uria J, Del Pozo J, Bravo G et al (1978) Functional treatment of acromegaly by transphenoidal microsurgery. J Neurosurg 49:36–40CrossRefPubMed
5.
go back to reference García-Uría J, Lucas T, Bravo G. et al (1997) Acromegaly: long term results in 300 patients. J Endocrinol Invest 20(supl):98–100 García-Uría J, Lucas T, Bravo G. et al (1997) Acromegaly: long term results in 300 patients. J Endocrinol Invest 20(supl):98–100
6.
go back to reference Laws ER (1979) Neurosurgical management of acromegaly. Results in 82 patients treated between 1972–1977. J Neurosurg 50(4):454–461CrossRefPubMed Laws ER (1979) Neurosurgical management of acromegaly. Results in 82 patients treated between 1972–1977. J Neurosurg 50(4):454–461CrossRefPubMed
7.
go back to reference Giustina A, Chanson P, Bronstein MD et al (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95(7):3141–3148CrossRefPubMed Giustina A, Chanson P, Bronstein MD et al (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95(7):3141–3148CrossRefPubMed
8.
go back to reference Katznelson L, Laws ER, Melmed S et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3935CrossRefPubMed Katznelson L, Laws ER, Melmed S et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3935CrossRefPubMed
9.
go back to reference Melmed S, Casanueva F, Lamberts S, et al (2002) Guidelines form acromegaly management. J Clin Endocrinol Metab 87(9):4054–4058CrossRef Melmed S, Casanueva F, Lamberts S, et al (2002) Guidelines form acromegaly management. J Clin Endocrinol Metab 87(9):4054–4058CrossRef
12.
go back to reference Hardy J (1969) Surgery of the pituitary gland using transsphenoidal approach. Ann Chir 21(15):1011–22 Hardy J (1969) Surgery of the pituitary gland using transsphenoidal approach. Ann Chir 21(15):1011–22
13.
go back to reference Colao A, Attanasio R, Pivonello R et al (2006) Partial surgical removal of growth hormona-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 91(1):85–92CrossRefPubMed Colao A, Attanasio R, Pivonello R et al (2006) Partial surgical removal of growth hormona-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 91(1):85–92CrossRefPubMed
14.
go back to reference Campbell PG, Kenning E, Andrews DW et al (2010) Outcomes after a purely endoscopic transphenoidal resection of growth hormone-secreting pituitary adenomas. Neurosurg Focus 29(4):E5CrossRefPubMed Campbell PG, Kenning E, Andrews DW et al (2010) Outcomes after a purely endoscopic transphenoidal resection of growth hormone-secreting pituitary adenomas. Neurosurg Focus 29(4):E5CrossRefPubMed
15.
go back to reference Gondim JA, Almeida JP, Alburqueque LA et al (2010) Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center. Neurosurg Focus 95(7):3141–3148 Gondim JA, Almeida JP, Alburqueque LA et al (2010) Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center. Neurosurg Focus 95(7):3141–3148
16.
go back to reference Hazer DB, Isik S, Berker M (2013) Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria. J Neurosurg 119(6):1467–1477CrossRefPubMed Hazer DB, Isik S, Berker M (2013) Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria. J Neurosurg 119(6):1467–1477CrossRefPubMed
17.
go back to reference Hofstetter CP, Mannaa RH, Mubita L et al (2010) Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas. Neurosurg Focus 29(4):E6CrossRefPubMed Hofstetter CP, Mannaa RH, Mubita L et al (2010) Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas. Neurosurg Focus 29(4):E6CrossRefPubMed
18.
go back to reference Wagenmakers MA (2011) Results of endoscopic transsphenoidal pituitary surgery in 40 patients with a growth hormona-secreting adenomas. Acta Neurochir 153(7):1391–1399 Wagenmakers MA (2011) Results of endoscopic transsphenoidal pituitary surgery in 40 patients with a growth hormona-secreting adenomas. Acta Neurochir 153(7):1391–1399
19.
go back to reference Zada G, Cavallo L, Esposito F, et al (2010) Transsphenoidal Surgery in patients with acromegaly: operative strategies for overcoming technically challenging anatomical variations. Neurosurg Focus 29(4):E8.10 Zada G, Cavallo L, Esposito F, et al (2010) Transsphenoidal Surgery in patients with acromegaly: operative strategies for overcoming technically challenging anatomical variations. Neurosurg Focus 29(4):E8.10
Metadata
Title
Acromegaly: surgical results in 548 patients
Authors
Cecilia Fernández Mateos
Maria García-Uria
Tomás Lucas Morante
José García-Uría
Publication date
01-10-2017
Publisher
Springer US
Published in
Pituitary / Issue 5/2017
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-017-0813-y

Other articles of this Issue 5/2017

Pituitary 5/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine